Literature DB >> 22305685

Randomized trials in angioplasty and stenting of the renal artery: tabular review of the literature and critical analysis of their results.

Guillermo A Escobar1, Danielle N Campbell.   

Abstract

As the incidence of hypertension (HTN) continues to rise, finding the optimal treatment of this multifactorial disease is critical. Renal artery stenosis (RAS) is a known etiology for HTN and is associated with declining renal function. Other than medications, the original gold standard for treatment of HTN from RAS was with an open surgical revascularization or nephrectomy. Since then, endovascular interventions for RAS have been reported to be technically possible, but their efficacy over medications or surgery has yielded conflicting results in case series and randomized trials. This tabular review summarizes the results of randomized trials that compared the outcomes of endovascular renal artery interventions with nonendovascular techniques (including medical and surgical treatments) for the treatment of HTN and renal dysfunction. Based on these data, the strengths and weaknesses of individual trials are critically analyzed to better define the methods to identify and treat patients with RAS. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22305685     DOI: 10.1016/j.avsg.2011.11.003

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  3 in total

Review 1.  Renovascular hypertension: is there still a role for stent revascularization?

Authors:  Stephen C Textor
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-09       Impact factor: 2.894

Review 2.  Renal artery stenosis: medical versus interventional therapy.

Authors:  Stephen C Textor; Lilach O Lerman
Journal:  Curr Cardiol Rep       Date:  2013-10       Impact factor: 2.931

3.  Clinical effectiveness of secondary interventions for restenosis after renal artery stenting.

Authors:  Thomas A Simone; Benjamin S Brooke; Philip P Goodney; Daniel B Walsh; David H Stone; Richard J Powell; Jack L Cronenwett; Brian W Nolan
Journal:  J Vasc Surg       Date:  2013-05-18       Impact factor: 4.268

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.